- Home
- RDFN vs XNCR Comparison
RDFN vs XNCR Comparison
Compare RDFN & XNCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RDFN
- XNCR
- Stock Information
- Founded
- RDFN 2002
- XNCR 1997
- Country
- RDFN United States
- XNCR United States
- Employees
- RDFN N/A
- XNCR N/A
- Industry
- RDFN Real Estate
- XNCR Biotechnology: Pharmaceutical Preparations
- Sector
- RDFN Finance
- XNCR Health Care
- Exchange
- RDFN Nasdaq
- XNCR Nasdaq
- Market Cap
- RDFN 1.1B
- XNCR 1.3B
- IPO Year
- RDFN 2017
- XNCR 2013
- Fundamental
- Price
- RDFN $7.85
- XNCR $17.76
- Analyst Decision
- RDFN Hold
- XNCR Strong Buy
- Analyst Count
- RDFN 11
- XNCR 8
- Target Price
- RDFN $9.43
- XNCR $34.63
- AVG Volume (30 Days)
- RDFN 4.4M
- XNCR 534.5K
- Earning Date
- RDFN 02-25-2025
- XNCR 02-25-2025
- Dividend Yield
- RDFN N/A
- XNCR N/A
- EPS Growth
- RDFN N/A
- XNCR N/A
- EPS
- RDFN N/A
- XNCR N/A
- Revenue
- RDFN $1,016,774,000.00
- XNCR $85,164,000.00
- Revenue This Year
- RDFN $8.63
- XNCR N/A
- Revenue Next Year
- RDFN $9.90
- XNCR $80.86
- P/E Ratio
- RDFN N/A
- XNCR N/A
- Revenue Growth
- RDFN 3.70
- XNCR N/A
- 52 Week Low
- RDFN $5.10
- XNCR $15.31
- 52 Week High
- RDFN $15.29
- XNCR $27.24
- Technical
- Relative Strength Index (RSI)
- RDFN 44.93
- XNCR 28.92
- Support Level
- RDFN $7.58
- XNCR $19.15
- Resistance Level
- RDFN $8.78
- XNCR $19.45
- Average True Range (ATR)
- RDFN 0.46
- XNCR 0.97
- MACD
- RDFN 0.06
- XNCR -0.15
- Stochastic Oscillator
- RDFN 22.50
- XNCR 11.60
About RDFN Redfin Corporation
Redfin Corp is a residential real estate broker. It pairs its agents with the technology to create a service that is faster and costs less. The company meets customers through a listings-search website and mobile application. The company uses the same combination of technology and local service to originate mortgage loans and offer title and settlement services. It has five operating segments and three reportable segments, real estate services, rentals, and mortgage. The company generates the majority of its revenue from Real estate services.
About XNCR Xencor Inc.
Xencor Inc is a clinical-stage biopharmaceutical company based in the United States. It focuses on discovering and developing engineered monoclonal antibody and other protein therapeutics to treat severe and life-threatening diseases such with unmet medical needs. The company uses its XmAb technology platform to create antibody product candidates such as XmAb5871 and XmAb7195. It also has a few pre-clinical stage candidates in its portfolio such as XmAb14045, XmAb662 among others. It earns its revenue from research and development collaborations and licenses of its internally developed drug candidates.